arrow
J

Joanne Wilson

AstraZeneca
H指数:25
被引数:3,200

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Achieving human brain exposure with the oral ataxia-telangiectasia mutated kinase inhibitor AZD1390, a substrate of aldehyde oxidase

通过口服A-T突变酶抑制剂AZD1390(醛氧化酶底物)实现人脑暴露。

2025-06-030
PRE
Metabolism-driven in vitro/in vivo disconnect of an oral ERα VHL-PROTAC
2024-05-135
OAAI
Method To Visualize the Intratumor Distribution and Impact of Gemcitabine in Pancreatic Ductal Adenocarcinoma by Multimodal Imaging
2022-01-1024
PRE
AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib
2021-02-0516
OAAI
AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity
2019-11-07237
OAAI
Orally Bioavailable and Blood-Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice
2018-07-3154
OAAI
The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models
2018-06-01221
OAAI
The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one)
2018-04-23101
OAAI
Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists
2017-03-05308
OAAI
Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo
2016-02-10168
OAAI